Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Consistent with global data, lebrikizumab demonstrated clinical improvements with a positive benefit-risk profile in Japanese adults and adolescents with moderate-to-severe AD through 16 weeks.
Authors
- Hitoe Torisu‐Itakura (ORCID: https://orcid.org/0000-0002-3200-2882)
- Ken Igawa (ORCID: https://orcid.org/0000-0001-5574-198X)
- Norito Katoh (ORCID: https://orcid.org/0000-0002-3498-2482)
- Yoko Kataoka (ORCID: https://orcid.org/0000-0002-5121-0134)
- Ryosuke Shimizu (ORCID: https://orcid.org/0000-0001-9666-8678)
- Akio Tanaka
- Hidetoshi Takahashi
- Yoji Morisaki
Institutions
- Hiroshima University (JP)
- Kyoto Prefectural University (JP)
- Osaka Prefectural Medical Center (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka City Shimizu Hospital (JP)
- Eli Lilly (Japan) (JP)
- Takayanagi Dental Clinic (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1080/03007995.2024.2436982
- Citations
- 8
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.28